Wednesday, April 30, 2025 7:52:38 PM
That's because Alon Ben Noon doesn't file them on time. Sometimes you don't hear of the notice at all. You can tell one has been sent out because of the listing requirements for trading above $1.00 and if there's discrepancy there then surely the last filing for year end would have done it. They need 5 million cash or above to meet the threshold for minimum requirements to maintain nasdaq listing and they have been deficient for 5 months now considering the filing was for year end 2024. Right about now they have 0 in their bank accounts essentially broke
Recent NRSN News
- NeuroSense Announces Pricing of Insider-Led PIPE Financing • PR Newswire (US) • 04/28/2026 06:30:00 PM
- NeuroSense Granted Brazilian Patent Covering PrimeC Composition • PR Newswire (US) • 04/06/2026 01:20:00 PM
- NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements • PR Newswire (US) • 04/03/2026 02:02:00 PM
- NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update • PR Newswire (US) • 03/31/2026 01:20:00 PM
- NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout • PR Newswire (US) • 03/24/2026 01:00:00 PM
- /C O R R E C T I O N -- NeuroSense/ • PR Newswire (US) • 03/18/2026 02:44:00 PM
- PrimeC New Data to Be Presented at AD/PD™ 2026 Conference • PR Newswire (US) • 03/18/2026 12:00:00 PM
- JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity • PR Newswire (US) • 03/16/2026 03:33:00 PM
- PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference • PR Newswire (US) • 03/09/2026 03:07:00 PM
- NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition • PR Newswire (US) • 02/09/2026 02:20:00 PM
- World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB • PR Newswire (US) • 01/08/2026 01:45:00 PM
- NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study • PR Newswire (US) • 12/22/2025 02:17:00 PM
- NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 • PR Newswire (US) • 12/04/2025 12:30:00 PM
- NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS • PR Newswire (US) • 11/24/2025 02:56:00 PM
- NeuroSense to Host Investor Webinar on December 8, 2025 • PR Newswire (US) • 11/03/2025 02:15:00 PM
- NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers • PR Newswire (US) • 10/06/2025 01:00:00 PM
- NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons • PR Newswire (US) • 09/10/2025 06:30:00 PM
- NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price • PR Newswire (US) • 09/04/2025 12:49:00 PM
- NeuroSense Provides Business Update and Progress for the First Half of 2025 • PR Newswire (US) • 08/01/2025 01:00:00 PM
- Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community • PR Newswire (US) • 07/22/2025 12:42:00 PM
